RxDoctor Payments Data

Julie Schallhorn, MD

Ophthalmology · Los Angeles, CANPI 1700014321

Payments from drug & device makers

$187,713in general payments, 2019–2025

Across 179 payments — averaging $1048.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$96K
  • Johnson & Johnson Surgical Vision, Inc.$38K
  • Oyster Point Pharma, Inc.$32K
  • Vanda Pharmaceuticals Inc.$5K
  • Carl Zeiss Meditec USA, Inc.$3K
  • Tarsus Pharmaceuticals, Inc.$3K
  • plus $10K from 15 others
$1,875in research payments, 2019–2025

Across 1 payment — averaging $1875.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Oyster Point Pharma, Inc.$2K

What the payments were for

  • Consulting fees$104,31067%
  • Speaking & faculty fees$22,73215%
  • Travel & lodging$17,37111%
  • Food & beverage$8,9256%
  • Gifts$170%
  • Other$2,0971%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$187,713 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$177,846
Medicare patients
263
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate172$8,984
MoxifloxacinMoxifloxacin Hcl153$6,389
Fluorometholone47$5,421
TafluprostTafluprost/Pf12$1,823
Brimonidine Tartrate21$1,784
Dorzolamide-TimololDorzolamide/Timolol/Pf13$1,004
Difluprednate13$917
ValacyclovirValacyclovir Hcl12$837
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim74$578
Ketorolac Tromethamine26$400
Latanoprost25$386
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat21$264
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha13$197

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →